KRAS and BRAF mutations are found in 30-50% and 10% of metastatic colorectal cancer (mCRC) patients respectively. Here we report a unique case of mCRC with coexistent KRAS and BRAF mutations. Patients harboring concomitant KRAS and BRAF mutations do not usually respond to standard chemotherapeutic regimens, usually have aggressive course of illness with poor prognosis and we are in dire need of developing new treatment strategies.
Liver Diseases Branch, NIDDK, NIH, Bethesda, MD, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Division of Medical Oncology, The University of Kansas Medical Center, Kansas City, Kansas, USA.
View Book :- http://bp.bookpi.org/index.php/bpi/catalog/book/161